Williamson Joseph, Black Louisa, Black Anna, Koduri Gouri, Kelly Clive
Sheffield University, Sheffield, UK.
Walsall Hospital, Walsall, UK.
Ir J Med Sci. 2022 Feb;191(1):1-5. doi: 10.1007/s11845-021-02545-y. Epub 2021 Feb 10.
There is considerable overlap between the clinical manifestations of covid-19 pneumonia and the acute interstitial lung disease seen in certain rheumatic disorders. In addition, pulmonary fibrosis is increasingly recognised as a potentially serious consequence of both.
This review explores this overlap of clinical features, risk factors and causation, offering insights into the immune mechanisms that contribute to both sets of disorders.
The therapeutic role of immunosuppression and biologic agents in the treatment of covid-19 is explained in the light of this.
We propose how lessons learned from the insights recently gained into each disorder can improve our insight into immunological mechanisms and application of therapeutic interventions in the other.
新型冠状病毒肺炎（COVID-19）的临床表现与某些风湿性疾病中出现的急性间质性肺病之间存在相当大的重叠。此外，肺纤维化日益被认为是这两种疾病潜在的严重后果。
本综述探讨了临床特征、危险因素和病因方面的这种重叠，深入了解了导致这两组疾病的免疫机制。
据此解释了免疫抑制和生物制剂在治疗COVID-19中的治疗作用。
我们提出，从最近对每种疾病的深入了解中吸取的经验教训如何能增进我们对免疫机制的理解，以及如何将治疗干预应用于另一种疾病。
